
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova has demonstrated an operating margin improvement of 180 basis points year-over-year, driven by gross margin expansion and strategic SG&A leverage, indicating strong operational efficiency. The company is projected to achieve mid-single-digit revenue growth of 6.7% for 2024, with expectations for cardiopulmonary organic growth of 7.0-8.0% in 2025, bolstered by the launch of the Essenz HLM and increased market share in oxygenators. Additionally, LivaNova's capacity for oxygenator production has improved by 10% in 2024, with anticipated further enhancements of 10-15% in 2025, positioning the company well for future revenue growth as elective procedures rebound post-pandemic.
Bears say
LivaNova's recent financial performance indicates a concerning trend, with neuromodulation sales growing only 1.0% to $137.6 million, a significant decline from the 8.8% growth observed in the previous quarter, and challenges in its OUS epilepsy business due to personnel changes. While cardiopulmonary sales experienced an 11.2% increase, this was also a decrease from the previous quarter's 15.4% growth, suggesting potential headwinds in sustaining momentum across key segments. Furthermore, the company's guidance indicates a slowdown in organic revenue growth to 7% for 4Q24, down from 12% in 3Q24, alongside expectations of operating margin contraction, contributing to a bearish outlook on its future performance.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares